FAQs - The Robert A. Winn Diversity in Clinical Trials Award Program

Q: Why is the Winn CDA focused on the disease areas of cancer, cardiovascular disease and immunologic disorders?

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] These are the therapeutic focus areas of the program funding partners. The strategy of the partners is to fund innovative demonstration projects in these areas. [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Why is the Winn CDA focused on the disease areas of cancer, cardiovascular disease and immunologic disorders?

winnawards2024-01-31T12:46:55-05:00August 25, 2023|

What is the goal of Winn CDA?

winnawards2023-09-26T01:23:40-05:00August 25, 2023|